(A) Policy Statement

The Blood Transfusion Service dispenses Rh Immune Globulin to patients when indicated.

(B) Purpose of Policy

To prevent Rh immunization in Rh negative patients exposed to the D antigen.

(C) Procedure

Potential candidates for Rh Immune Globulin therapy should have the following studies done according to the Transfusion Service procedure manual:

- ABO grouping
- D testing
- Antibody screening
- Identification of all clinically significant antibodies, if present.

It is the responsibility of the attending physician to assure the Rh type has been determined on patients admitted for delivery, spontaneous abortion, pregnant abdominal trauma or invasive obstetrical procedures. The requirement for determination of Rh type can be fulfilled by consulting previous records, providing the tests were done by a laboratory accredited by the AABB or by the College of American Pathologists, or certified by HCFA, or licensed by the FDA. Document the results obtained by the outside laboratory in the BBIS system if the testing laboratory is not UTMC.

Patients who demonstrate anti-D in the serum are not candidates for Rh Immune Globulin therapy. Consult patient's physician to rule out antepartum Rh Immune Globulin administration as a cause of detectable anti-D. Women who have received antepartum Rh Immune Globulin are candidates for additional treatment postpartum. All patients at risk for feto-maternal hemorrhage with weak reactions to anti-D should be microscopically examined for mixed field reaction to rule out large fetal bleed. Use caution in interpreting such results as Rh positive. Deliveries are not routine at UTMC, therefore, quantitation of fetal bleed is not part of this laboratory's standard procedure. Refer quantitation tests to another laboratory, if appropriate.

Rh negative patients transfused with Rh positive cellular products may also be candidates for Rh Immune Globulin prophylaxis. Notify the BTS Medical Director when Rh positive cellular products are transfused to Rh negative recipients. The BTS Medical Director will discuss options with the attending physician and who will initiate orders for Rh Immune prophylaxis for appropriate candidates.
When a candidate for Rh Immune Globulin therapy is identified, the prophylaxis shall be administered within 72 hours of the immunizing event. Notify BTS Medical Director when orders are not received for RhIg for eligible candidates or the ordered dose is not dispensed for injection within 72 hours.